KMDA - Kamada Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.23
-0.03 (-0.57%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.26
Open5.36
Bid4.62 x 1200
Ask5.38 x 800
Day's Range5.23 - 5.33
52 Week Range4.35 - 6.45
Volume3,401
Avg. Volume8,845
Market Cap209.572M
Beta (3Y Monthly)1.23
PE Ratio (TTM)21.79
EPS (TTM)0.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.33
Trade prices are not sourced from all markets
  • CVS will offer home delivery of prescriptions
    Yahoo Finance Video7 months ago

    CVS will offer home delivery of prescriptions

    In an effort to stave off Amazon, CVS will roll-out nationwide delivery of prescription medication. Yahoo Finance's Seana Smith, Ethan Wolff-Mann, David Pogue and Rick Newman discuss.

  • Biotech and energy top list for best paying jobs
    Yahoo Finance Video8 months ago

    Biotech and energy top list for best paying jobs

    Engineers in both the energy and biotech sectors are among top earners, surpassing Wall Street. Yahoo Finance's Seana Smith, Jennifer Rogers and Pras Subramanian discuss.

  • GlobeNewswire16 days ago

    Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018

    Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today preliminary and unaudited total revenues for the fourth quarter and full-year 2018.  Total revenue for the fourth quarter of 2018 is expected to be between $46.7 million and $48.7 million.  Total revenue for full-year 2018 is expected to be between $113 million and $115 million. Kamada’s initial full-year 2018 total revenue guidance of $116 million to $120 million was previously revised to $102 million to $108 million as a result of the now settled labor strike at the Company’s Beit Kama production facility in Israel.

  • Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates

    Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Kamada: 3Q Earnings Snapshot

    The Rehovot, Israel-based company said it had a loss of 6 cents per share. Losses, adjusted for stock option expense, came to 5 cents per share. The biopharmaceutical posted revenue of $15 million in the ...

  • GlobeNewswire2 months ago

    Kamada Reports Financial Results for Third Quarter and First Nine Months of 2018

    Total Revenues for First Nine Months of 2018 were $66.3 Million, a 1% Decrease Year-Over-YearGross Profit for First Nine Months of 2018 was $20.2 million, a  1% Decrease.

  • GlobeNewswire2 months ago

    Kamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12

    REHOVOT, Israel, Nov. 05, 2018 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.

  • GlobeNewswire3 months ago

    Kamada Announces Appointment of Life Sciences Industry Executive Eitan Kyiet as Vice President of Business Development

    Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Eitan Kyiet as Vice President of Business Development.  Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry. Mr. Kyiet will report directly to Amir London, Kamada’s Chief Executive Officer.

  • PR Newswire5 months ago

    Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board

    Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, Board of Directors is proud to announce its addition of Dr Giloz-Ran, former manager of Grants Capital Investment, at INTEL Corporation, Israel - to its advisory board. "We are honored to have Dr. Giloz-Ran join our Board of Advisors, her exceptional record in international business management suits us well as our state-of-the-art laboratory comes into operation and we are being approached by potential medical partners to explore joint ventures," said Eyal Ballan, CTO.

  • The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
    Zacks5 months ago

    The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants

    The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants

  • Dollar Strengthens on Turkey's Trouble: Top 5 Gainers
    Zacks5 months ago

    Dollar Strengthens on Turkey's Trouble: Top 5 Gainers

    Lira loses more than 20% over the week as international markets react to the uncertainty over Turkey's capability to repay foreign-currency debts. Dollar hits a one-year high.

  • Kamada (KMDA) Surpasses Q2 Earnings and Revenue Estimates
    Zacks5 months ago

    Kamada (KMDA) Surpasses Q2 Earnings and Revenue Estimates

    Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 months ago

    Kamada: 2Q Earnings Snapshot

    On a per-share basis, the Rehovot, Israel-based company said it had profit of 14 cents. The biopharmaceutical posted revenue of $33.8 million in the period. Kamada shares have climbed 22 percent since ...

  • ACCESSWIRE5 months ago

    Kamada Ltd to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Kamada Ltd (NASDAQ: KMDA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern Time. To listen ...

  • Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?
    Zacks7 months ago

    Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

    Is (KMDA) Outperforming Other Medical Stocks This Year?

  • 4 Undervalued MedTech Stocks to Consider Amid Volatility
    InvestorPlace7 months ago

    4 Undervalued MedTech Stocks to Consider Amid Volatility

    The U.S. medical device industry has exhibited strong and sustainable growth of late due to an aging population and increasing incidences of chronic and lifestyle diseases. Elimination of the tax will result in huge savings for the medical device players, in turn compelling them to focus on innovation. Per consulting specialist Emergo, the U.S. medical device industry was valued at $147.7 billion in 2016 and is projected to grow significantly through 2019 to $173 billion.

  • 5 Biotech Stocks Under $10 Worthy of Investors' Attention
    Zacks7 months ago

    5 Biotech Stocks Under $10 Worthy of Investors' Attention

    Small biotech stocks are good bets with lower market cap as well as share price.